WilmerHale Represents Fulcrum Therapeutics in Series A Financing from GV

  • 5.10.2017

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of its lead programs in Fragile X syndrome and Fascioscapularhumeral muscular dystrophy.
The WilmerHale team representing Fulcrum Therapeutics includes Lia Der Marderosian, Stephanie Singer and Byron Crowe.
Read Fulcrum Therapeutics' press release for more information.

See other News & Publications related to:

See related industries:

Life Sciences